Abstract
Cell therapy using human embryonic stem cells (hESCs) is a promising therapeutic option for Parkinson's disease (PD), an incurable neurodegenerative disease. A prerequisite for clinical application of hESCs for PD is an efficient and strict differentiation of hESCs into midbrain dopamine (mDA) neuron-like cells, which would be directly translated into high effectiveness of the therapy with minimum risk of undesirable side effects. Due to fruitful efforts from many laboratories, a variety of strategies for improving efficiency of dopaminergic differentiation from hESCs have been developed, mostly by optimizing culture conditions, genetic modification, and modulating intracellular signaling pathways. The rapid advances in the fields of dopaminergic differentiation of hESCs, prevention of tumor formation, and establishment of safe human induced pluripotent stem cells (hiPSCs) would open the door to highly effective, tumor-free, and immune rejection-free cell therapy for PD in the near future.
| Original language | English |
|---|---|
| Pages (from-to) | 292-301 |
| Number of pages | 10 |
| Journal | Journal of cellular biochemistry |
| Volume | 109 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2010 Feb 1 |
| Externally published | Yes |
Keywords
- Dopamine neuron differentiation
- Human ES/IPS cells
- Pakinson's disease
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Cell Biology
